Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: endocrine, other_emerging
- Who it enrolls
- age 18 Years to 40 Years; female; excludes diabetes; BMI ≥25 required; conditions: Polycystic Ovary Syndrome
- Interventions
- Metformin; Exenatide 2 MG
- Conditions
- Polycystic Ovary Syndrome
- Phase and size
- Phase 4 · 80 participants
- Dates
- Start 2019-07-20
Primary completion 2020-02-28 - Sponsor
- Peking Union Medical College Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change in body weightPatient's body weight was measured at the baseline and after 12 weeks of clinical trial
Published results in the collection
- Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndromeRandomized trial · 2021 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
02Eligibility
Who can take part
Inclusion Criteria: * Females 18 years to 40 years of age * Diagnosed as PCOS by the 2003 Rotterdam criteria. * Overweight/obesity (BMI≥25 kg/m2) * No pregnant plan in recent 6 months * Written consent for participation in the study Exclusion Criteria: * type 1 or type 2 diabetes mellitus * Subjects have other endocrine diseases, such as adrenal hyperplasias or tumor, androgen-secreting tumors, Cushing's syndrome, thyroid diseases, and hyperprolactinemia * Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Serious systemic disease or malignant tumor * History of pancreatitis (chronic, acute or recurrent) * Body weight change ≥10% at 3 months before treatment * Used oral contraceptives or sex hormone drugs in the past 1 month * Used oral glucocorticoids in the past 1 month * Substance (alcohol or drug) abuse or dependence within 3 months; Heavy smokers (smokers who smoke 20 or more cigarettes a day) or heavy drinkers (\>10g/d) * Subjects have a severe systemic disease, such as cardiovascular system * Renal impairment, eGFR\<60ml/min/1.73m2 * Increase of transaminases up to \< 2.5 times of upper limit of normal value * Have a history of thromboembolic disease or thrombotic tendency * Subjects in pregnant or lactating or within 1 year after delivery. * Subjects have an allergic history to the drugs used in the study * Subjects have participated in other clinical researches of medicine within 1 month prior to randomization. * Use of metformin, glucagon-like peptide -1 receptor agonists, or weight loss medications (prescription or OTC) within 30 days before screening.
03Change log
Registry changes
No changes recorded since the trial was added.